Full text is available at the source.
The Cochrane database of systematic reviews··
Bupropion treatment for adults with ADHD
Updated
Abstract
A total of 438 participants were included across six studies evaluating bupropion for adult ADHD.
- Low-quality evidence suggests that bupropion may decrease the severity of ADHD symptoms, with a standardized mean difference of -0.50.
- The proportion of participants achieving clinical improvement could be increased by bupropion, with a risk ratio of 1.50.
- Bupropion may lead to a higher likelihood of reporting improvements on the Clinical Global Impression - Improvement scale, with a risk ratio of 1.78.
- The rate of withdrawal due to adverse effects appears similar between bupropion and placebo groups.
- The overall quality of evidence is rated low due to serious risk of bias and small sample sizes.
- Further research is necessary to clarify the treatment's efficacy and optimal target population.
Simplified
BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.
OBJECTIVES: To assess the effects and safety of bupropion for the treatment of adults with ADHD.
SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and seven other databases in February 2017. We also searched three trials registers and three online theses portals. In addition, we checked references of included studies and contacted study authors to identify potentially relevant studies that were missed by our search.
SELECTION CRITERIA: We included all randomised controlled trials (RCTs) that evaluated the effects (including adverse effects) of bupropion compared to placebo in adults with ADHD.
DATA COLLECTION AND ANALYSIS: Two review authors (WV, GB) independently screened records and extracted data using a data extraction sheet that we tested in a pilot study. We extracted all relevant data on study characteristics and results. We assessed risks of bias using the Cochrane 'Risk of bias' tool, and assessed the overall quality of evidence using the GRADE approach. We used a fixed-effect model to pool the results across studies.
MAIN RESULTS: We included six studies with a total of 438 participants. Five studies were conducted in the USA, and one in Iran. All studies evaluated a long-acting version of bupropion, with the dosage ranging from 150 mg up to 450 mg daily. Study intervention length varied from six to 10 weeks. Four studies explicitly excluded participants with psychiatric comorbidity and one study included only participants with opioid dependency. Four studies were funded by industry, but the impact of this on study results is unknown. Two studies were publicly funded and in one of these studies, the lead author was a consultant for several pharmaceutical companies and also received investigator-driven funding from two companies, however none of these companies manufacture bupropion. We judged none of the studies to be free of bias because for most risk of bias domains the study reports failed to provide sufficient details. Using the GRADE approach, we rated the overall quality of evidence as low. We downgraded the quality of the evidence because of serious risk of bias and serious imprecision due to small sample sizes.We found low-quality evidence that bupropion decreased the severity of ADHD symptoms (standardised mean difference -0.50, 95% confidence interval (CI) -0.86 to -0.15, 3 studies, 129 participants), and increased the proportion of participants achieving clinical improvement (risk ratio (RR) 1.50, 95% CI 1.13 to 1.99, 4 studies, 315 participants), and reporting an improvement on the Clinical Global Impression - Improvement scale (RR 1.78, 95% CI 1.27 to 2.50, 5 studies, 337 participants). There was low-quality evidence that the proportion of participants who withdrew due to any adverse effect was similar in the bupropion and placebo groups (RR 1.20, 95% CI 0.35 to 4.10, 3 studies, 253 participants). The results were very similar when using a random-effects model and when we analysed only studies that excluded participants with a psychiatric comorbidity.
AUTHORS' CONCLUSIONS: The findings of this review, which compared bupropion to placebo for adult ADHD, indicate a possible benefit of bupropion. We found low-quality evidence that bupropion decreased the severity of ADHD symptoms and moderately increased the proportion of participants achieving a significant clinical improvement in ADHD symptoms. Furthermore, we found low-quality evidence that the tolerability of bupropion is similar to that of placebo. In the pharmacological treatment of adults with ADHD, extended- or sustained-release bupropion may be an alternative to stimulants. The low-quality evidence indicates uncertainty with respect to the pooled effect estimates. Further research is very likely to change these estimates. More research is needed to reach more definite conclusions as well as clarifying the optimal target population for this medicine. Treatment response remains to be reported in a DSM5-diagnosed population. There is also a lack of knowledge on long-term outcomes.
Related papers
Jan '21
Fast-acting methylphenidate for treating ADHD in adults
cited by 13 papers
systematic review
Aug '18
Amphetamines used to treat ADHD in adults
cited by 56 papers
systematic review
Feb '22
Long-lasting methylphenidate treatment for adult ADHD
cited by 10 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 29 papers
systematic review
Nov '15
Methylphenidate treatment for children and teens with ADHD
cited by 166 papers
systematic review
Dec '25
Methylphenidate use in children and teens with ADHD
cited by 2 papers
systematic review
Mar '23
Methylphenidate treatment for children and teens with ADHD
cited by 45 papers
systematic review
May '18
Side Effects of Methylphenidate for ADHD in Children and Teens from Non-Randomized Studies
cited by 175 papers
systematic review
Nov '17
Methylphenidate use in children and teens with autism
cited by 58 papers
systematic review
Sep '14
Fast-acting methylphenidate for treating adult ADHD
cited by 37 papers
systematic review